Abstract

Aims & Objectives:
To elucidate the clinical presentation, diagnosis,
histopathology, management, and treatment outcomes of
DICC with a focus on cases resulting from anti-glaucoma
medications (AGM).
Materials & Methods:
A comprehensive literature review was conducted alongside
a case series investigation of 12 patients diagnosed with
AGM-induced DICC. These patients' clinical presentations,
medications history, and outcomes post-diagnosis were
evaluated.
Results:
The predominant cause of DICC in the observed cohort was
preserved AGM (12 cases). At the point of diagnosis, more
than 70% of eyes exhibited punctal scarring, inflammation,
and forniceal shortening. Diagnosis primarily rested on the
rapid alleviation of symptoms and inflammation after the
cessation of suspected medications, with a response
window ranging from 1-16 weeks.
Comclusion:
The primary inciting agents of DICC are preserved AGM, emphasizing
the need for awareness in prescription practices.